DAFTAR PUSTAKA

[1] S. Mahadeva and K. L. Goh, "Epidemiology of functional dyspepsia: A global perspective," *World J. Gastroenterol.*, vol. 12, no. 17, pp. 2661–2666, 2006, doi: 10.3748/wjg.v12.i17.2661.

[2] S. K. Rupp and A. Stengel, "Bi-Directionality of the Microbiota-Gut-Brain Axis in Patients With Functional Dyspepsia: Relevance of Psychotherapy and Probiotics," *Front. Neurosci.*, vol. 16, no. February, pp. 1–15, 2022, doi: 10.3389/fnins.2022.844564.

[3] X. Zhang *et al.*, "Duodenal microbiota dysbiosis in functional dyspepsia and its potential role of the duodenal microbiota in gut–brain axis interaction: a systematic review," *Front. Microbiol.*, vol. 15, no. August, 2024, doi: 10.3389/fmicb.2024.1409280.

[4] A. Y. Arnaout *et al.*, "The prevalence and risk factors of functional dyspepsia among adults in low- and middle-income countries: An international cross-sectional study," *Med. (United States)*, vol. 102, no. 40, p. E35437, 2023, doi: 10.1097/MD.0000000000035437.

[5] Kementerian Kesehatan RI, *Profil Kesehatan Indonesia 2022*. 2023.

[6] Dinkes Jateng, "Tengah Tahun 2023 Jawa Tengah," *Buku Profil Kesehat. Provinsi Jawa Teng. Tahun 2023*, p. 267, 2023.

[7] S. Tahun, D. Eka, P. Nusu, T. S. Tuloli, and E. N. Djuwarno, "Ketepatan Penggunaan Obat Dispepsia Pada Pasien Rawat Inap di Rumah Sakit Umum Daerah Prof . Dr . H . Aloei," no. 2, pp. 1–17, 2026.

[8] M. D. Ariska, A. Primadiamanti, and M. P. Angin, "Evaluasi Rasionalitas Penggunaan Obat Pada Pasien Dispepsia Di Puskesmas Penawar Jaya, Kabupaten Tulang Bawang, Lampung," *J. Farm. Malahayati*, vol. 6, no. 1, pp. 111–124, 2023.

[9] F. D. Sema, E. D. Asres, and B. D. Wubeshet, "Evaluation of Rational Use of Medicine Using WHO / INRUD Core Drug Use Indicators at Teda and Azezo," *Integr. Pharm. Res. Pract.*, vol. 10, pp. 51–63, 2021.

[10] D. S. Strand, D. Kim, and D. A. Peura, "25 years of proton pump inhibitors: A comprehensive review," *Gut Liver*, vol. 11, no. 1, pp. 27–37, 2017, doi: 10.5009/gnl15502.

[11] D. N. Mardika, S. D. Astuti, and T. Wijayanti, "Analisis Hubungan Rasionalitas Penggunaan Obat Antihipertensi dengan Keberhasilan Terapi

Pasien Rawat Inap Rumah Sakit X Tahun 2022," *J. Farm. Komunitas*, vol. 11, no. 1, pp. 16–21, 2024, doi: 10.20473/jfk.v11i1.48594.

[12] D. A. Drossman, "Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV," *Gastroenterology*, vol. 150, no. 6, pp. 1262-1279.e2, 2016, doi: 10.1053/j.gastro.2016.02.032.

[13] K. Dan, K. Dispepsia, and F. Dyspepsia, "Indonesian Journal of Nursing and Health Sciences," vol. 2, pp. 57–64, 2021.

[14] V. Stanghellini *et al.*, "Gastroduodenal disorders," *Gastroenterology*, vol. 150, no. 6, pp. 1380–1392, 2016, doi: 10.1053/j.gastro.2016.02.011.

[15] A. C. Ford, A. Marwaha, R. Sood, and P. Moayyedi, "Global prevalence of, and risk factors for, uninvestigated dyspepsia: A meta-analysis," *Gut*, vol. 64, no. 7, pp. 1049–1057, 2015, doi: 10.1136/gutjnl-2014-307843.

[16] N. A. F. Nugroho, A. E. Nugroho, and P. Probosuseno, "Efektivitas Kombinasi Terapi Prokinetik dengan Proton Pump Inhibitor (PPI) pada Pasien Dispepsia," *Maj. Farm.*, vol. 21, no. 3, p. 258, 2025, doi: 10.22146/farmaseutik.v21i3.105923.

[17] H. Miwa *et al.*, "Evidence-based clinical practice guidelines for functional dyspepsia 2021," *J. Gastroenterol.*, vol. 57, no. 2, pp. 47–61, 2022, doi: 10.1007/s00535-021-01843-7.

[18] P. M. Moayyedi, B. E. Lacy, C. N. Andrews, R. A. Enns, C. W. Howden, and N. Vakil, "ACG and CAG Clinical Guideline: Management of Dyspepsia," *Am. J. Gastroenterol.*, vol. 112, no. 7, pp. 988–1013, 2017, doi: 10.1038/ajg.2017.154.

[19] C. J. Black *et al.*, "British Society of Gastroenterology guidelines on the management of functional dyspepsia," *Gut*, vol. 71, no. 9, pp. 1697–1723, 2022, doi: 10.1136/gutjnl-2022-327737.

[20] Aisyah Hartiningrum *et al.*, "Profil Pengetahuan dan Faktor Risiko terkait Dispepsia Pada Mahasiswa Fakultas Non Kesehatan serta Ketepatan Tindakan Penanganannya," *J. Farm. Komunitas*, vol. 11, no. 2, pp. 134–142, 2024, doi: 10.20473/jfk.v11i2.52908.

[21] M. Swords, "Symposium - Hindfoot and Ankle Trauma," *Indian*, vol. 52, no. may, pp. 161–169, 2018, doi: 10.4103/ortho.IJOrtho.

[22] K. Diseases, "Histamine Type-2 Receptor Antagonists (H2 Blockers)," no. Md, pp. 1–6, 2018.

[23] E. M. M. Quigley, “Prokinetics in the Management of Functional Gastrointestinal Disorders,” *Curr. Gastroenterol. Rep.*, vol. 19, no. 10, pp. 330–336, 2017, doi: 10.1007/s11894-017-0593-6.

[24] P. Malfertheiner *et al.*, “Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report,” *Gut*, vol. 71, no. 9, pp. 1724–1762, 2022, doi: 10.1136/gutjnl-2022-327745.

[25] K. Upadhya R, L. Shenoy, and R. Venkateswaran, “Effect of intravenous dexmedetomidine administered as bolus or as bolus-plus-infusion on subarachnoid anesthesia with hyperbaric bupivacaine,” *J. Anaesthesiol. Clin. Pharmacol.*, vol. 34, no. 3, pp. 46–50, 2018, doi: 10.4103/joacp.JOACP.

[26] K. K. Ri, “Modul penggunaan obat rasional,” 2011.

[27] I. P. Primanda *et al.*, “Rumah Sakit Swasta Di Purwokerto,” vol. 9, no. 2, 2024.

[28] “farmalkes.kemkes.go.id,” pp. 1–219, 2023.

[29] Ari et.al, “Ari 2021,” 2021. [Online]. Available: file:///C:/Users/ASUS/AppData/Local/Microsoft/Windows/INetCache/IE/DMXKUF5F/Konsensus-Nasional-Penatalaksanaan-Dispepsia-dan-Infeksi-H.pylori-di-Indonesia-Revisi-2021[1].pdf

[30] Sugiono Kakek, *Metode Penelitian Kuantitatif*.

[31] S. A. Adiputra, M. S., Trisnadewi, W., Oktaviani, P. W., Munthe, “Metodologi penelitian kesehatan,” *Yayasan Kita Menulis*, p. 326, 2021.

[32] K. Abdullah *et al.*, *Metode Penelitin Kuantitatif*.

[33] ISO *et al.*, “IDENTITAS Judul,” *Mater. Sci. Eng. A*, vol. 16, no. 6, pp. 1–19, 2010, [Online]. Available: http://dx.doi.org/10.1016/j.engfailanal.2008.01.004%0Ahttp://dx.doi.org/10.1016/j.engfracmech.2008.11.011%0Ahttp://dx.doi.org/10.1016/j.corsci.2009.12.020%0Ahttp://dx.doi.org/10.1016/j.corsci.2009.11.044%0Ahttp://dx.doi.org/10.1016/j.biotechadv.2010.07.00

[34] K. Lee *et al.*, “Global prevalence of functional dyspepsia according to Rome criteria, 1990–2020: a systematic review and meta-analysis,” *Sci. Rep.*, vol. 14, no. 1, pp. 1–11, 2024, doi: 10.1038/s41598-024-54716-3.

[35] S. Hari, G. L. Burns, E. C. Hoedt, and S. Keely, “Eosinophils , Hypoxia-Inducible Factors , and Barrier Dysfunction in Functional Dyspepsia,” vol. 3, no. May, pp. 1–13, 2022, doi: 10.3389/falgy.2022.851482.

[36] A. F. Syam *et al.*, “Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report,” *Gut Pathog.*, vol. 15, no. 1, pp. 1–19, 2023, doi: 10.1186/s13099-023-00551-2.

[37] V. V. L. Minh Tuan Pham1*, Anh Tuan Hoang2, Anh Tuan Le1, Abdel Rahman M.Said Al-Tawaha3, Van Huong Dong2, “No Title 済無No Title No Title No Title,” vol. 2, pp. 306–312, 2024.

[38] European Medicines Agency, “CMDh confirms recommendations on restricting use of domperidone-containing medicines,” *EMA website*, vol. 44, no. April, 2014, [Online]. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/04/news_detail_002083.jsp&mid=WC0b01ac058004d5c1

[39] S. Wongrakpanich, A. Wongrakpanich, K. Melhado, and J. Rangaswami, “A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly,” *Aging Dis.*, vol. 9, no. 1, pp. 143–150, 2018, doi: 10.14336/AD.2017.0306.

[40] R. Sohail *et al.*, “Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review,” *Cureus*, vol. 15, no. 4, pp. 1–14, 2023, doi: 10.7759/cureus.37080.

[41] L. E. Targownik, D. A. Fisher, and S. D. Saini, “AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review,” *Gastroenterology*, vol. 162, no. 4, pp. 1334–1342, 2022, doi: 10.1053/j.gastro.2021.12.247.

[42] A. Ghamar-Shooshtari *et al.*, “Polypharmacy and pattern of medication use among patients with gastroesophageal reflux disease: results from Pars Cohort study,” *BMC Gastroenterol.*, vol. 23, no. 1, pp. 1–9, 2023, doi: 10.1186/s12876-023-03086-7.

[43] L. B. Ou, C. Moriello, A. Douros, and K. B. Filion, “Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta-analysis of observational studies,” *Br. J. Clin. Pharmacol.*, vol. 87, no. 10, pp. 3649–3658, 2021, doi: 10.1111/bcp.14737.

[44] J. Chaves, I. Pita, D. Libânio, and P. Pimentel-Nunes, “Pharmacological Treatment of Functional Dyspepsia: An Old Story Revisited or a New Story to Be Told? A Clinical Review,” *GE Port. J. Gastroenterol.*, vol. 30, no. 2, pp. 86–97, 2023, doi: 10.1159/000526674.

[45] T. Kitano *et al.*, “Long-Term Outcomes After Therapeutic Induction in

Patients with Functional Dyspepsia," *J. Clin. Med.*, vol. 14, no. 22, pp. 1–15, 2025, doi: 10.3390/jcm14228224.

[46] P. Singh *et al.*, "Clinical and Psychological Factors Predict Outcome in Patients With Functional Dyspepsia: A Prospective Study," *Clin. Gastroenterol. Hepatol.*, vol. 20, no. 6, pp. 1251-1258.e1, 2022, doi: 10.1016/j.cgh.2021.07.043.